Report Overview

The global single-cell omics market is poised for significant growth, with a projected valuation of USD 1.40 billion as of 2022. Anticipated to expand at a CAGR of 16.1% from 2023 to 2030, this market is driven by transformative innovations in single-cell analysis and the increasing adoption of large-scale genomics studies utilizing single-cell RNA sequencing. Furthermore, the burgeoning biotechnology and biopharmaceutical sectors, coupled with escalating demand for biologics, are fueling market expansion. The rising prevalence of life-threatening conditions has also amplified the need for personalized medicine, thereby propelling market growth forward.

The COVID-19 pandemic catalyzed a surge in demand for cutting-edge technologies that can better understand viral-host interactions, immune response, and cell types affected by the virus. Furthermore, researchers leveraged this technology to create precision diagnostics, which pinpoint specific markers. With chronic diseases on the rise and an increasing need for innovative treatments, this field is poised for significant growth opportunities.

As the global landscape of cancer continues to evolve, so too does our understanding of its intricacies. The alarming rise in cancer cases is being paralleled by an increasing reliance on single-cell analysis to unravel the complexities of cancer progression. In fact, according to the Canadian government's data, cancer stands as a leading cause of mortality in the country. Moreover, the Canadian Cancer Society estimates that approximately 2 in 5 Canadians will be affected by cancer at some point during their lifetime. The integration of single-cell omics analysis is poised to revolutionize our comprehension of cancer biology, enabling a more nuanced identification of various immune subsets and shedding light on overall tumor progression. Furthermore, individual cellular omics allows for the meticulous analysis of individual cells, thereby facilitating accurate diagnoses and monitoring treatment efficacy.

The advent of cutting-edge single-cell technologies has revolutionized our understanding of biological processes by allowing researchers to glean valuable insights from individual cells. As a result, the emergence of advanced single-cell platforms has significantly enhanced cellular separation and analysis, piquing the interest of scientists across various disciplines. Consequently, the growing demand for novel single-cell analysis tools is driving manufacturers to introduce innovative products into the market. For example, in June 2021, Cellenion and SCIENION collaborated to launch cellenCHIP 384, a single-cell omics sample preparation platform that expanded the company's automated capabilities and high-throughput workflows. This launch marked an exciting milestone in the development of single-cell analysis technologies, offering researchers unprecedented opportunities for discovery and exploration.

The growing significance of single-cell omics has significantly boosted its adoption across various fields, including cell biology and personalized medicine. Furthermore, an increasing enthusiasm for single-cell analysis research and rising funding initiatives are expected to propel market expansion. For example, in November 2022, the Texas AM University System secured a USD 1.19 million grant from NIH to harness single-cell sequencing technology, with a focus on enhancing cancer diagnosis, treatment, and prevention.

The emergence of multi-omics has revolutionized this field, enhancing data efficiency and quality through a concurrent analysis of multiple analytes using advanced techniques such as sample splitting, combined analysis, or class switching. For instance, transcriptomes represent a prime example of this approach, leveraging sequencing technologies like CITE-seq by Illumina to sequence RNA within cells while employing barcoded antibodies that target cell surface epitopes, thereby capturing the cellular indexing process.

Product Type Insights

The single-cell genomics segment has consistently dominated the market, accounting for 45.8% of total revenue in 2022. The sector's rapid growth can be attributed to a multifaceted array of factors, including escalating demand from an extensive range of end-users, promising clinical applications of single-cell genomics platforms, and significant technological advancements. These breakthroughs have empowered researchers to unravel cellular heterogeneity with unparalleled precision, thanks to innovations such as microfluidics, high-throughput sequencing platforms, and droplet-based methods.

The growing demand for single-cell level sequencing capabilities is being driven by market players seeking to enhance their offerings. The recent announcement by Singular Genomics Systems, Inc., in February 2023, of Max Read kits specifically designed for single-cell applications on the C4 sequencing platform, further reinforces this trend. This innovative product aims to not only increase experiment output but also reduce overall costs, ultimately supporting segment growth.

The burgeoning interest in metabolomics, coupled with escalating investment from both governmental and private entities, is fueling a surge in research endeavors aimed at accelerating metabolomics advancements. Furthermore, the expanding applications of single-cell metabolomics in disease research and its pronounced potential in cancer diagnostics are poised to propel the segment into a period of accelerated growth.

Application Insights

The oncology segment dominated the single-cell omics market in 2022, accounting for 55.1% of the share. This segment is poised to continue its growth trajectory, with a projected high growth rate from 2023 to 2030. The increasing prevalence of cancer worldwide, combined with advancements in single-cell analysis techniques and the adoption of omics-based tools for studying cancer progression, are driving this growth. China's reported 4.57 million cancer cases and 3 million deaths in 2020 highlight the need for innovative approaches to combat the rising burden of cancer globally. The use of omics-based tools is crucial in understanding tumor heterogeneity and analyzing tumor cell behavior, ultimately enhancing diagnosis accuracy and treatment efficacy.

The growing demand for personalized cancer treatment has driven the adoption of cutting-edge technologies, including single-cell genomics. As precision medicine gains momentum, market leaders like Mission Bio, CYTENA, and Illumina are at the forefront, providing innovative solutions to support diagnosis and monitoring of various cancers.

The immunology sector is poised for significant growth, with a projected CAGR of 15.9% over the forecast period, second only to the therapeutics segment. This rapid expansion can be attributed to ongoing research studies, supportive government legislation, and a robust demand for cutting-edge treatments. Furthermore, the increasing adoption of single-cell omics technology has further fueled segment growth by enabling the development of innovative immunotherapies and therapeutic antibodies.

End-User Insights.

The academic and research organizations segment held the largest share of approximately 42.8% in the end-user market in 2022. The growing adoption of technology on college campuses, coupled with an increase in research initiatives aimed at developing innovative modeling tools, is expected to propel this segment forward. Furthermore, a surge in research studies by various institutes aimed at exploring diverse applications of cellular biology is also anticipated to drive growth in this segment. Notably, researchers are currently investigating the vast potential of single-cell technologies across multiple disciplines, including transcriptomics, genomics, proteomics, epigenomics, and metabolomics. For example, in March 2023, Schmidt Futures allocated USD 550 million to a new research facility focused on advancing single-cell proteomics technologies.

The pharmaceutical and biotech sectors are intensifying their focus on creating cutting-edge targeted therapeutics, bolstering RD investments, and forging partnerships to accelerate drug discovery. This uptick is expected to propel segmental growth. Furthermore, collaborations among companies to develop innovative technologies are fueling further expansion of the sector. For example, in February 2023, Ultima Genomics, Inc partnered with 10x Genomics to seamlessly integrate chromium single-cell applications onto ultima sequencers.

Regional Insights

North America dominated the global market share in 2022, accounting for a significant 46.37% of the total market presence. The region's growth can be attributed to several key factors, including the proliferation of multiple market players and their ongoing developments, which have fueled regional expansion. Furthermore, the presence of advanced healthcare infrastructure and an increase in research and development activities aimed at cultivating novel technologies are also contributing to the region's success. Government support through legislation, the rising significance of cellular therapies, and the growing trend towards precision medicine are additional drivers propelling the regional market forward. For example, the U.S. has initiated a precision medicine initiative with the aim of enhancing health outcomes and treating diseases more effectively.

The Asia Pacific region is poised for significant growth, with a projected CAGR of 17.8% from 2023 to 2030. This rapid expansion can be attributed to the increasing burden of target diseases and the rising demand for advanced therapeutics. As a result, the single-cell omics market in this region is expected to experience substantial growth. Furthermore, market players are keenly exploring untapped opportunities, leading to increased investments and strategic partnerships in the region. Notably, collaborations between companies, such as the agreement signed by Mission Bio and SequMed in December 2021, which enabled seamless leveraging of offerings in China, highlight the potential for further regional expansion.

Key Companies Market Share Insights

The single-cell omics industry is witnessing a surge in intense competition as several major players are vying to expand their market share. To gain a competitive edge, these companies are engaging in strategic initiatives such as mergers, acquisitions, and partnerships. For example, Flugent Genetics recently launched the Mission Bio, Inc. platform in April 2023, aiming to increase accessibility of single-cell multi-omics for clinical research and drug development purposes. This move is expected to significantly enhance Fulgent Genetics' capabilities in the drug development space. Notably, several prominent players are actively contributing to the global single-cell omics market, including:

• Danaher Corporation

• CYTENA GmbH

• 10x Genomics

• BD

• CELLENION

• PerkinElmer Inc.

• ANGLE plc

• Illumina, Inc.

• Bio-Rad Laboratories, Inc.

• Mission Bio

• Standard BioTools Inc.

Recent Developments

• In February 2023, BD introduced a new tool for single-cell multi-omics analysis. It allows researchers to conduct high-throughput studies without compromising sample integrity, potentially accelerating the pace of discovery across a variety of fields.

• In June 2021, SCIENION and Cellenion launched cellenCHIP 384 for single-cell omics sample preparation, available as a consumable in the new cellenCHIP 384 - 3'RNA-seq Kit for scalable, nanoliter volume library creation of single cells.

Single-cell Omics Market Report Scope

Get A Free Sample Research Report PDF

 https://www.theresearchinsights.com/reports/single-cell-omics-market-446/request-sample

Global Single-cell Omics Market Report Segmentation

This comprehensive report offers insights into the future revenue prospects for the single-cell omics market, presenting a detailed breakdown at both global and regional levels. Spanning from 2018 to 2030, it delves into the latest industry trends in each sub-segment, providing valuable information for stakeholders across various sectors. The report is segmented by product type, application, end-user, and region to offer a nuanced understanding of market dynamics.

• Product Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Single-Cell Genomics

  • Single-Cell Transcriptomics

  • Single-Cell Proteomics

  • Single-Cell Metabolomics

• Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Cell Biology

  • Neurology

  • Immunology

• End-User Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical Biotechnology Companies

  • Academic and Research Organizations

  • Hospital and Diagnostic Laboratories

  • Others

• Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • The U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait